DAB2IP in cancer

Liang Liu; Cong Xu; Jer-Tsong Hsieh; Jianping Gong; Daxing Xie

doi:10.18632/oncotarget.6501

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

DAB2IP in cancer

Liang Liu, Cong Xu, Jer-Tsong Hsieh, Jianping Gong and Daxing Xie _

PDF | HTML | How to cite

Oncotarget. 2016; 7:3766-3776. https://doi.org/10.18632/oncotarget.6501

Metrics: PDF 2889 views | HTML 2877 views | ?

Abstract

Liang Liu1,2,*, Cong Xu3,*, Jer-Tsong Hsieh4, Jianping Gong1,2, Daxing Xie1,2

1Tongji Cancer Research Institute, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

2Department of Gastrointestinal Surgery, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

3Department of Gastroenterology, Tongji Hospital, Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei 430030, China

4Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

*These authors contributed equally to this work

Correspondence to:

Daxing Xie, e-mail: [email protected]

Jianping Gong, e-mail: [email protected]

Jer-Tsong Hsieh, e-mail: [email protected]

Keywords: DAB2IP, AIP1, cancer, tumor suppressor

Received: July 23, 2015 Accepted: November 15, 2015 Published: December 08, 2015

ABSTRACT

DOC-2/DAB2 is a member of the disable gene family that features tumor-inhibiting activity. The DOC-2/DAB2 interactive protein, DAB2IP, is a new member of the Ras GTPase-activating protein family. It interacts directly with DAB2 and has distinct cellular functions such as modulating different signal cascades associated with cell proliferation, survival, apoptosis and metastasis. Recently, DAB2IP has been found significantly down regulated in multiple types of cancer. The aberrant alteration of DAB2IP in cancer is caused by a variety of mechanisms, including the aberrant promoter methylation, histone deacetylation, and others. Reduced expression of DAB2IP in neoplasm may indicate a poor prognosis of many malignant cancers. Moreover, DAB2IP stands for a promising direction for developing targeted therapies due to its capacity to inhibit tumor cell growth in vitro and in vivo. Here, we summarize the present understanding of the tumor suppressive role of DAB2IP in cancer progression; the mechanisms underlying the dysregulation of DAB2IP; the gene functional mechanism and the prospects of DAB2IP in the future cancer research.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6501

Publication Alerts

Reviews:

DAB2IP in cancer

Abstract